Abstract Number: 953 • 2019 ACR/ARP Annual Meeting
Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data
Background/Purpose: In RA patients not meeting treat-to-target goals despite treatment with a biologic (b)DMARD, ACR guidelines1 recommend using other targeted immunomodulators (TIM): TNF-α inhibitor (TNFi),…Abstract Number: 1156 • 2019 ACR/ARP Annual Meeting
Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) generates high impact on patients and healthcare systems. Adequate control of disease activity depends to a large extent on the access…Abstract Number: 1342 • 2019 ACR/ARP Annual Meeting
Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease with a fluctuating course of disease activity and progression. Although treatments have improved substantially in recent…Abstract Number: 1369 • 2019 ACR/ARP Annual Meeting
Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy
Background/Purpose: Previously, we demonstrated the direct pro-inflammatory role of the vascular endothelial growth factor (VEGF) and the placenta growth factor (PlGF), and angiogenic factors in…Abstract Number: 1396 • 2019 ACR/ARP Annual Meeting
Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Background/Purpose: Understanding persistence of biologic therapies and factors associated with discontinuation can help inform treatment decisions for patients with rheumatoid arthritis (RA). We sought to…Abstract Number: 1434 • 2019 ACR/ARP Annual Meeting
Improvement in Matrix metalloproteinase-3 Levels at 12 Weeks Independently Predicts Achievement of Low Disease Activity at 52 Weeks in Bio-switch Patients with Rheumatoid Arthritis Treated with Abatacept
Background/Purpose: Japanese post-marketing surveillance (PMS) data demonstrated that effectiveness of abatacept in rheumatoid arthritis (RA) patients with previous biologics treatment (bio-switch) was significantly lower than…Abstract Number: 1886 • 2019 ACR/ARP Annual Meeting
Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Background/Purpose: Novel antibody systems including anti-carbamylated protein antibody (anti-CarP IgG) and anti-peptidyl arginine deiminase antibody (anti-PAD4 IgG) are emerging as independent diagnostic and prognostic biomarkers…Abstract Number: 1998 • 2019 ACR/ARP Annual Meeting
Major Histocompatibility Antigen HLA-DQB1*0601 Is Associated with Rheumatoid Arthritis Among Indians in a Replication Study: Evidence of Gene-Environment Interaction with LPG Stove Use
Background/Purpose: Shared epitope smoking interaction does not fully explain MHC association in Rheumatoid Arthritis (RA). We have previously shown HLA-DQB1*0601 (DQ6.1) to be a susceptibility…Abstract Number: 2133 • 2019 ACR/ARP Annual Meeting
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Background/Purpose: Inflammation is a risk factor in the development of cardiovascular disease. The proposed etiology centers around accelerated atherosclerosis involving various cytokines in the TNF…Abstract Number: 2288 • 2019 ACR/ARP Annual Meeting
Pregnancy Outcomes in Women Exposed to Golimumab
Background/Purpose: Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic…Abstract Number: 2320 • 2019 ACR/ARP Annual Meeting
Knowledge of Cardiovascular Disease Risk Among Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a significantly higher risk of cardiovascular disease (CVD) than general population. The Heart Disease Fact Questionnaire (HDFQ-RA 1…Abstract Number: 2339 • 2019 ACR/ARP Annual Meeting
Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is an extra-articular manifestation with a poor prognosis. In clinical practice, to establish such a diagnosis requires…Abstract Number: 2364 • 2019 ACR/ARP Annual Meeting
Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development
Background/Purpose: Lymphoproliferative disorders (LPD) remains as a major problem to resolve among the patients with rheumatoid arthritis (RA). During few decades, rheumatic therapy has dramatically…Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…Abstract Number: 2772 • 2019 ACR/ARP Annual Meeting
Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet
Background/Purpose: RA patients often inquire about dietary interventions to improve disease control, as they perceive quick changes in pain and/or swelling after consumption of certain…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 56
- Next Page »